I use Windows 11, which recently offered me a Microsoft COPILOT (AI) button. I asked it about the molecular lab startup Harbinger Health.
Copilot correctly found it had raised $140M and started clinical studies. However, it incorrectly said it was part of DELOITTE (I had asked a prior question that involved Deloitte). It gave me the low value news that it's not related to a restaurant in Des Moines or dengue fever in Brazel.
Two other sources for integrated web news and AI are "Perplexity" and "You.com". Perplexity gave me the answer further below. Perplexity gave a similar summary to MS Copilot but without the incorrect or nonsensical additions. You.com did a nice job but without hits for the clinical studies.
Note that Google now likely starts its lists of returned hits with its own Google-summary at top.
MS COPILOT
Harbinger Health is a biotechnology company that is developing a platform for early detection of multiple cancers1. According to the latest news, Harbinger Health has:
- Started a new clinical study in individuals at high risk for cancer1.
- Raised $140 million in Series B funding to accelerate the advancement of its screening platform1.
- Expanded its industry-leading executive team with new appointments1.
- Announced data demonstrating high sensitivity of its multi-cancer detection platform at the AACC Annual Scientific Meeting 2023 and the ASCO Annual Meeting 202312.
Harbinger Health is part of Deloitte, and its co-founder is Keeley, who also developed the framework of the Ten Types of Innovation3. Harbinger Health is not related to Harbinger, a restaurant in Des Moines, IA, that was named one of the best restaurants in the US4. Harbinger Health is also not involved in the outbreaks of bubonic plague or dengue fever that have been reported in Oregon and Brazil, respectively53.
PERPLEXITY
Harbinger Health is a diagnostics company focused on early cancer detection. The company is pioneering the development of blood-based tests for the early detection of cancer, with a vision of making cancer screening accessible and affordable to all. In recent news, Harbinger Health has expanded its executive team, adding industry experts to drive the company's growth and advance its product platform. Additionally, the company has launched a clinical study in partnership with the Sarah Cannon Research Institute to further develop and validate its early cancer detection platform. Furthermore, Harbinger Health recently secured $140 million in new funding to support its work in cancer diagnostics [Provides 6 links as numbered buttons, otherwise unlabeled].
YOU.COM
Harbinger Health is a diagnostics company that is focused on transforming the detection, diagnosis, and treatment of cancer. Founded in 2018, the company combines unique insights into the biology of cancer with artificial intelligence and machine learning to develop high-resolution blood-based assays for early cancer detection 1.
The company's vision is to enable early therapeutic interventions by identifying cancer before it becomes visible or symptomatic. By detecting cancer in its pre-disease state, Harbinger Health aims to create a new pathway for cancer diagnosis and make it a routine health problem that can be addressed with early intervention 2.
Harbinger Health has recently raised $140 million in Series B funding to further its mission of revolutionizing cancer care. The funding will support the development of low-cost, multi-cancer blood tests and contribute to the company's goal of preventing cancer formation rather than just treating its spread 3.
The company's innovative approach and potential impact on cancer care have attracted significant attention and support from investors and the industry. Harbinger Health has also expanded its executive team, bringing in experienced professionals from leading diagnostics companies to drive its growth and success 4.
For more information about Harbinger Health and its mission, you can visit their website at www.harbinger-health.com or follow them on Twitter (@harbingerhlth) and LinkedIn.
